Literature DB >> 29296768

Patient-derived xenografts of low-grade B-cell lymphomas demonstrate roles of the tumor microenvironment.

W Richard Burack1, Janice M Spence1, John P Spence1, Stephen A Spence1, Philip J Rock1, Gautam N Shenoy2, Leonard D Shultz3, Richard B Bankert2, Steven H Bernstein4.   

Abstract

To discern features of non-Hodgkin lymphomas (NHL) that are autonomous from those that are shaped by the tumor environment (TE), we used patient-derived xenografts (PDX) to probe the effects on neoplastic cells of manipulating the TE. Properties of neoplastic cells that are often considered to be autonomous include their relative independence from stromal support, their relative survival and/or proliferation advantages compared with nonneoplastic cells, and their state of differentiation. Prior approaches to creation of PDX models likely select for neoplasms, which are the most capable of engraftment, potentially masking the effects of the TE. To overcome this bias, we developed a robust protocol that rapidly produced xenografts with more than 85% of unselected, cryo-preserved, B-cell NHL specimens, including low-grade tumors such as follicular and marginal zone lymphoma. To discern features that are shaped by the TE, we extensively studied 4 low-grade lymphoma specimens. B-cell engraftment required components of the native TE; specifically, CD4+ cells. The relative survival of neoplastic compared with nonneoplastic B cells was not autonomous in 2 specimens; specifically, neoplastic B cells from 2 specimens showed a greater dependence on the TE than normal B cells for engraftment. Furthermore, the differentiation of neoplastic B cells was dependent on the TE; mature B-cell neoplasms converted to plasmacytoma-like lesions in the grafts. These results highlight the central and patient-specific roles of the TE in maintaining the relative survival of neoplastic cells compared with normal cells and in controlling the differentiation of neoplastic cells.

Entities:  

Year:  2017        PMID: 29296768      PMCID: PMC5728547          DOI: 10.1182/bloodadvances.2017005892

Source DB:  PubMed          Journal:  Blood Adv        ISSN: 2473-9529


  24 in total

1.  Demonstration of array-based analysis for highly multiplexed PCR assays application to detection of IGH@-BCL2 translocations in FFPE follicular lymphoma specimens.

Authors:  Janice M Spence; Paul G Rothberg; Nancy Wang; W Richard Burack
Journal:  J Mol Diagn       Date:  2011-05       Impact factor: 5.568

2.  Chronic lymphocytic leukemia cells diversify and differentiate in vivo via a nonclassical Th1-dependent, Bcl-6-deficient process.

Authors:  Piers E M Patten; Gerardo Ferrer; Shih-Shih Chen; Rita Simone; Sonia Marsilio; Xiao-Jie Yan; Zachary Gitto; Chaohui Yuan; Jonathan E Kolitz; Jacqueline Barrientos; Steven L Allen; Kanti R Rai; Thomas MacCarthy; Charles C Chu; Nicholas Chiorazzi
Journal:  JCI Insight       Date:  2016-04-07

3.  Deregulated BCL6 expression recapitulates the pathogenesis of human diffuse large B cell lymphomas in mice.

Authors:  Giorgio Cattoretti; Laura Pasqualucci; Gianna Ballon; Wayne Tam; Subhadra V Nandula; Qiong Shen; Tongwei Mo; Vundavalli V Murty; Riccardo Dalla-Favera
Journal:  Cancer Cell       Date:  2005-05       Impact factor: 31.743

4.  The omentum is a site of protective IgM production during intracellular bacterial infection.

Authors:  Derek D Jones; Rachael Racine; Susan T Wittmer; Louise Harston; Amber M Papillion; Lisa M Dishaw; Troy D Randall; David L Woodland; Gary M Winslow
Journal:  Infect Immun       Date:  2015-03-16       Impact factor: 3.441

5.  E mu-BRD2 transgenic mice develop B-cell lymphoma and leukemia.

Authors:  Rebecca J Greenwald; Joseph R Tumang; Anupama Sinha; Nicolas Currier; Robert D Cardiff; Thomas L Rothstein; Douglas V Faller; Gerald V Denis
Journal:  Blood       Date:  2003-10-16       Impact factor: 22.113

Review 6.  The tumour microenvironment in B cell lymphomas.

Authors:  David W Scott; Randy D Gascoyne
Journal:  Nat Rev Cancer       Date:  2014-07-10       Impact factor: 60.716

7.  The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice.

Authors:  Elizabeth C Townsend; Mark A Murakami; Alexandra Christodoulou; Amanda L Christie; Johannes Köster; Tiffany A DeSouza; Elizabeth A Morgan; Scott P Kallgren; Huiyun Liu; Shuo-Chieh Wu; Olivia Plana; Joan Montero; Kristen E Stevenson; Prakash Rao; Raga Vadhi; Michael Andreeff; Philippe Armand; Karen K Ballen; Patrizia Barzaghi-Rinaudo; Sarah Cahill; Rachael A Clark; Vesselina G Cooke; Matthew S Davids; Daniel J DeAngelo; David M Dorfman; Hilary Eaton; Benjamin L Ebert; Julia Etchin; Brant Firestone; David C Fisher; Arnold S Freedman; Ilene A Galinsky; Hui Gao; Jacqueline S Garcia; Francine Garnache-Ottou; Timothy A Graubert; Alejandro Gutierrez; Ensar Halilovic; Marian H Harris; Zachary T Herbert; Steven M Horwitz; Giorgio Inghirami; Andrew M Intlekofer; Moriko Ito; Shai Izraeli; Eric D Jacobsen; Caron A Jacobson; Sébastien Jeay; Irmela Jeremias; Michelle A Kelliher; Raphael Koch; Marina Konopleva; Nadja Kopp; Steven M Kornblau; Andrew L Kung; Thomas S Kupper; Nicole R LeBoeuf; Ann S LaCasce; Emma Lees; Loretta S Li; A Thomas Look; Masato Murakami; Markus Muschen; Donna Neuberg; Samuel Y Ng; Oreofe O Odejide; Stuart H Orkin; Rachel R Paquette; Andrew E Place; Justine E Roderick; Jeremy A Ryan; Stephen E Sallan; Brent Shoji; Lewis B Silverman; Robert J Soiffer; David P Steensma; Kimberly Stegmaier; Richard M Stone; Jerome Tamburini; Aaron R Thorner; Paul van Hummelen; Martha Wadleigh; Marion Wiesmann; Andrew P Weng; Jens U Wuerthner; David A Williams; Bruce M Wollison; Andrew A Lane; Anthony Letai; Monica M Bertagnolli; Jerome Ritz; Myles Brown; Henry Long; Jon C Aster; Margaret A Shipp; James D Griffin; David M Weinstock
Journal:  Cancer Cell       Date:  2016-04-11       Impact factor: 31.743

8.  Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells.

Authors:  Sandeep S Dave; George Wright; Bruce Tan; Andreas Rosenwald; Randy D Gascoyne; Wing C Chan; Richard I Fisher; Rita M Braziel; Lisa M Rimsza; Thomas M Grogan; Thomas P Miller; Michael LeBlanc; Timothy C Greiner; Dennis D Weisenburger; James C Lynch; Julie Vose; James O Armitage; Erlend B Smeland; Stein Kvaloy; Harald Holte; Jan Delabie; Joseph M Connors; Peter M Lansdorp; Qin Ouyang; T Andrew Lister; Andrew J Davies; Andrew J Norton; H Konrad Muller-Hermelink; German Ott; Elias Campo; Emilio Montserrat; Wyndham H Wilson; Elaine S Jaffe; Richard Simon; Liming Yang; John Powell; Hong Zhao; Neta Goldschmidt; Michael Chiorazzi; Louis M Staudt
Journal:  N Engl J Med       Date:  2004-11-18       Impact factor: 91.245

9.  Induction of proliferation of human follicular (B type) lymphoma cells by cognate interaction with CD4+ T cell clones.

Authors:  D T Umetsu; L Esserman; T A Donlon; R H DeKruyff; R Levy
Journal:  J Immunol       Date:  1990-04-01       Impact factor: 5.422

10.  Stromal gene signatures in large-B-cell lymphomas.

Authors:  G Lenz; G Wright; S S Dave; W Xiao; J Powell; H Zhao; W Xu; B Tan; N Goldschmidt; J Iqbal; J Vose; M Bast; K Fu; D D Weisenburger; T C Greiner; J O Armitage; A Kyle; L May; R D Gascoyne; J M Connors; G Troen; H Holte; S Kvaloy; D Dierickx; G Verhoef; J Delabie; E B Smeland; P Jares; A Martinez; A Lopez-Guillermo; E Montserrat; E Campo; R M Braziel; T P Miller; L M Rimsza; J R Cook; B Pohlman; J Sweetenham; R R Tubbs; R I Fisher; E Hartmann; A Rosenwald; G Ott; H-K Muller-Hermelink; D Wrench; T A Lister; E S Jaffe; W H Wilson; W C Chan; L M Staudt
Journal:  N Engl J Med       Date:  2008-11-27       Impact factor: 91.245

View more
  7 in total

Review 1.  In Vitro and In Vivo Models of CLL-T Cell Interactions: Implications for Drug Testing.

Authors:  Eva Hoferkova; Sona Kadakova; Marek Mraz
Journal:  Cancers (Basel)       Date:  2022-06-23       Impact factor: 6.575

2.  PHLPP2 is regulated by competing endogenous RNA network in pathogenesis of colon cancer.

Authors:  Hong-Kun Wu; Chang Liu; Xin-Xing Li; Wei Ji; Chen-De Xin; Zhi-Qian Hu; Lin Zhou
Journal:  Aging (Albany NY)       Date:  2020-07-07       Impact factor: 5.682

3.  Preclinical evaluation of cancer immune therapy using patient-derived tumor antigen-specific T cells in a novel xenograft platform.

Authors:  Gautam N Shenoy; Christopher J Greene; Maulasri Bhatta; Miren L Baroja; Jenni L Loyall; Sathy V Balu-Iyer; Raymond J Kelleher; Beatriz M Carreno; Gerald P Linette; Leonard D Shultz; Richard B Bankert
Journal:  Clin Transl Immunology       Date:  2021-02-02

4.  Novel phosphatidylserine-binding molecule enhances antitumor T-cell responses by targeting immunosuppressive exosomes in human tumor microenvironments.

Authors:  Maulasri Bhatta; Gautam N Shenoy; Jenni L Loyall; Brian D Gray; Meghana Bapardekar; Alexis Conway; Hans Minderman; Raymond J Kelleher; Beatriz M Carreno; Gerald Linette; Leonard D Shultz; Kunle Odunsi; Sathy V Balu-Iyer; Koon Yan Pak; Richard B Bankert
Journal:  J Immunother Cancer       Date:  2021-10       Impact factor: 13.751

Review 5.  Tumor-Associated Exosomes: A Potential Therapeutic Target for Restoring Anti-Tumor T Cell Responses in Human Tumor Microenvironments.

Authors:  Gautam N Shenoy; Maulasri Bhatta; Richard B Bankert
Journal:  Cells       Date:  2021-11-13       Impact factor: 6.600

6.  Tumor Microenvironment and Microvascular Density in Follicular Lymphoma.

Authors:  Roberto Tamma; Giuseppe Ingravallo; Tiziana Annese; Francesco Gaudio; Tommasina Perrone; Pellegrino Musto; Giorgina Specchia; Domenico Ribatti
Journal:  J Clin Med       Date:  2022-02-25       Impact factor: 4.241

7.  Complex genetic and histopathological study of 15 patient-derived xenografts of aggressive lymphomas.

Authors:  Radek Jakša; Jana Karolová; Michael Svatoň; Dmitry Kazantsev; Martina Grajciarová; Eva Pokorná; Zbyněk Tonar; Magdalena Klánová; Lucie Winkowska; Diana Maláriková; Petra Vočková; Kristina Forsterová; Nicol Renešová; Alexandra Dolníková; Kristýna Nožičková; Pavel Dundr; Eva Froňková; Marek Trněný; Pavel Klener
Journal:  Lab Invest       Date:  2022-04-29       Impact factor: 5.502

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.